Skip to content

Xuanbai Shengmai Granules as Adjuvant Therapy for Sepsis: A Randomized, Controlled Clinical Trial

Xuanbai Shengmai Granules as Adjuvant Therapy for Sepsis: A Randomized, Controlled Clinical Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002254
Enrollment
Unknown
Registered
2025-11-21
Start date
2023-10-23
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

Experimental Group:Routine treatment for sepsis + Xuanbai Shengmai Decoction

Sponsors

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Meets the diagnostic criteria for sepsis; (2) Aged 18–80 years; (3) Voluntarily participates in the study and has signed informed consent.

Exclusion criteria

Exclusion criteria: (1) Pregnant or lactating women; (2) Shock or death occurring within 48 hours of admission; (3) Vegetative state; (4) Confirmed or highly suspected acute infectious diseases, such as active viral hepatitis or active pulmonary tuberculosis; (5) Allergy to the active ingredient or excipients of the investigational drug; (6) Participation in any clinical intervention trial within the past 3 months.

Design outcomes

Primary

MeasureTime frame
28-day mortality rate;

Secondary

MeasureTime frame
Sequential Organ Failure Assessment;Acute Physiology and Chronic Health Evaluation II;Severe complication incidence rate;Hospitalization Days;Blood Oxygen Saturation;Partial pressure of oxygen in the artery;Partial pressure of arterial carbon dioxide;White blood cell count;Neutrophil percentage;lymphocyte count;C-reactive protein;Erythrocyte Sedimentation Rate;D-dimer;Troponin I;Troponin T;Brain natriuretic peptide;Serum Creatinine;Urea nitrogen;Alanine Aminotransferase;Glutamic-oxaloacetic transaminase;Blood Proteomics;Blood Metabolomics;Blood Single-Cell Sequencing Analysis;Fecal Metabolomics;Fecal microbiota diversity analysis;

Countries

China

Contacts

Public ContactYang Siwen

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University

yangsiwen@bjzhongyi.com15011237160

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026